anna viola

Dr. anna viola

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
DPDaniela Pugliese
Daniela Pugliese
GPGiuseppe Privitera
Giuseppe Privitera
FCFederica Crispino
Federica Crispino
NMNicolò Mezzina
Nicolò Mezzina
FCFabiana Castiglione
Fabiana Castiglione
IGIG‐IBD LIVE Study Group
IG‐IBD LIVE Study Group
Summary: Background: Vedolizumab registration trials were the first to include elderly patients with moderate‐to‐severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real‐life data have been reported in this population.Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients.Methods: The Long‐term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective‐prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019.Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p = 0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p = 0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti‐TNF‐α agents, Charlson comorbidity index >2 and moderate‐to‐severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events.Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age‐dependent effect on effectiveness was observed in CD.

1 April 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
AFAgnese Favale
Agnese Favale
SOSara Onali
Sara Onali
FCFlavio Andrea Caprioli
Flavio Andrea Caprioli
DPDaniela Pugliese
Daniela Pugliese
AAAlessandro Armuzzi
Alessandro Armuzzi
I(Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerative colitis (UC) patients who failed infliximab (IFX). Although, a comparative efficacy evaluation of ADA and VDZ in this clinical setting is currently missing. The aim of this study is to compare the efficacy of ADA and VDZ in patients affected by UC who failed IFX. Clinical records of UC patients from 8 Italian IBD referral centers who failed IFX and were candidates to receive either ADA or VDZ were retrospectively reviewed. The primary end point was therapeutic failure at week 52. Secondary end points included therapy discontinuation at weeks 8, 24 and 52, the discontinuation-free survival, and safety. One hundred sixty-one UC patients, 15 (9.2%) primary, 83 (51.6%) secondary IFX failures, and 63 (39.2%) IFX intolerants were included. Sixty-four (40%) patients received ADA and 97 (60%) VDZ as second line therapy. At week 52, 37.5% and 28.9% of patients on ADA and VDZ, respectively, had therapeutic failure (P = 0.302). However, the failure rate was significantly higher in the ADA group as compared with VDZ group among IFX secondary failures (48.0% ADA vs 22.4%VDZ, P = 0.035). The therapy discontinuation-free survival was significantly higher in the group of IFX secondary failures who received VDZ as compared with ADA at both the univariate (P = 0.007) and multivariate survival analysis (OR 2.79; 95% CI, 1.23–6.34; P = 0.014). No difference in the failure and biologic discontinuation-free survival was observed in the IFX primary failure and intolerant subgroups. Vedolizumab might be the therapy of choice in those UC patients who showed secondary failure to IFX.

27 September 2021 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
MCMichele Francesco Chiappetta
Michele Francesco Chiappetta
AVanna viola
anna viola
MMMauro Mastronardi
Mauro Mastronardi
LTLaura Turchini
Laura Turchini
SCSonia Carparelli
Sonia Carparelli
WFWalter Fries
Walter Fries
. Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC) has been demonstrated in clinical trials, but few real-world data are available so far. The aim of this study was t...

1 January 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
WFWalter Fries
Walter Fries
AVanna viola
anna viola
NMNatalia Manetti
Natalia Manetti
IFIris Frankovic
Iris Frankovic
DPDaniela Pugliese
Daniela Pugliese
GFGionata Fiorino
Gionata Fiorino

1 November 2020 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
Fabio Salvatore MacalusoFabio Salvatore Macaluso
Fabio Salvatore Macaluso
WFWalter Fries
Walter Fries
SRSara Renna
Sara Renna
AVanna viola
anna viola
MMMarco Muscianisi
Marco Muscianisi
T(The Sicilian Network For Inflammatory Bowel Disease (Sn‐Ibd)
The Sicilian Network For Inflammatory Bowel Disease (Sn‐Ibd)
Background: Biologically naïve patients with inflammatory bowel disease treated with vedolizumab (VDZ) are largely underrepresented in real‐world cohorts. A multi‐centre, observational cohort study was performed on the effectiveness and safety of VDZ in biologically naïve subjects with Crohn’s disease (CD) and ulcerative colitis (UC).Methods: Data of consecutive biologically naïve patients with CD and UC treated with VDZ from July 2016 to December 2019 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease.Results: A total of 172 consecutive patients (CD: N = 88; UC: N = 84; median age 66.0 years) were included, with a median follow‐up of 58.8 weeks. After 14 weeks, a clinical response was reported in 68.2% of patients with CD and 67.9% of patients with UC treated with VDZ, including 45.5% patients in the CD group and 46.4% patients in the UC group who achieved steroid‐free remission. After 52 weeks, a clinical response was reported in 77.4% of CD and in 73.8% of UC patients treated with VDZ, including 59.7% patients in the CD group and 60.7% patients in the UC group who achieved steroid‐free remission.Conclusions: This study demonstrates the effectiveness and safety of VDZ as a first‐line biological, particularly among elderly patients.

30 October 2023 in Research in Psychotherapy: Psychopathology, Process and Outcome
Verified
Journal Article
Open access
PDF file
Gabriella MartinoGabriella Martino
Gabriella Martino
AVanna viola
anna viola
CVCarmelo Vicario
Carmelo Vicario
FBFederica Bellone
Federica Bellone
OSOrlando Silvestro
Orlando Silvestro
Antonino CatalanoAntonino Catalano
Antonino Catalano
A comprehensive investigation of psychological features in chronic patients is very important for tailoring effective treatments. In this study we tested anxiety, depression, health related quality of life (HR-QoL), alexithymia, coping styles, and defense mechanisms, in eighty-four patients with Crohn disease (CD) and ulcerative colitis (UC). Participants reported low to moderate HRQoL and anxiety, apart from alexithymia. Women experienced lower QoL and higher levels of anxiety and depressive symptoms. Coping and defense strategies were related to distress symptoms and QoL. Positive attitude and principalization, showed negative associations with depression, anxiety and alexithymia and were also found to be associated with mental health. CD patients used significantly more turning against objects (p=0.02) and projections (p=0.01) and UC patients used more reversal (p=0.04). Elderly women showed higher anxiety symptoms and lower perceived QoL. Multiple regression analysis revealed anxiety and depression were independently associated with QoL. Significant differences emerged in defense styles among CD and UC. CD participants used more maladaptive coping and defense styles which were related to mental distress, depression and anxiety, together with higher level of alexithymia. Findings suggest that psychological aspects play a key role in mental health in patients suffering from inflammatory bowel diseases. A multi-integrated clinical strategy including psychotherapeutic interventions should be considered in treating CD and UC.